Evidence map›Paper›PMID 38927203›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Incidence of Antibiotic Exposure for Suspected and Proven Neonatal Early-Onset Sepsis between 2019 and 2021: A Retrospective, Multicentre Study.

Liesanne E J van Veen, Bo M van der Weijden, Niek B Achten, Lotte van der Lee, Jeroen Hol, Maaike C van Rossem, Maarten Rijpert, Anna O J Oorthuys, Ron H T van Beek, Gerdien H Dubbink-Verheij and 10 more

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Liesanne E J van VeenDepartment of Paediatrics, Franciscus Gasthuis en Vlietland, Kleiweg 500, 3045 PM Rotterdam, The Netherlands.
Bo M van der WeijdenDepartment of Paediatrics, Tergooi MC, Laan van Tergooi 2, 1212 VG Hilversum, The Netherlands.ORCID 0000-0001-8977-8422
Niek B AchtenDepartment of Paediatrics, Erasmus MC University Medical Center, Sophia Children's Hospital, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Lotte van der LeeDepartment of Paediatrics, Amsterdam UMC, Emma Children's Hospital, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Jeroen HolDepartment of Paediatrics, Noordwest Hospital, Wilhelminalaan 12, 1815 JD Alkmaar, The Netherlands.
Maaike C van RossemDepartment of Paediatrics, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands.
Maarten RijpertDepartment of Paediatrics, Zaans Medical Centre, Kon. Julianaplein 58, 1502 DV Zaandam, The Netherlands.
Anna O J OorthuysDepartment of Paediatrics, Amsterdam UMC, Emma Children's Hospital, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-6661-9493
Ron H T van BeekDepartment of Paediatrics, Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands.ORCID 0000-0002-5275-1637
Gerdien H Dubbink-VerheijDepartment of Paediatrics, Groene Hart Hospital, Bleulandweg 10, 2803 HH Gouda, The Netherlands.
René F KornelisseDepartment of Neonatal and Paediatric Intensive Care, Division of Neonatology, Erasmus MC University Medical Center, Sophia Children's Hospital, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Laura H van der Meer-KapelleDepartment of Paediatrics, Reinier de Graaf Gasthuis, Reinier de Graafweg 5, 2625 AD Delft, The Netherlands.ORCID 0000-0002-7555-6359
Karen Van MechelenDepartment of Neonatology, Maastricht University Medical Center (MUMC+), MosaKids Children's Hospital, 6229 HX Maastricht, The Netherlands.ORCID 0000-0003-2853-2079
Suzanne BroekhuizenDepartment of Paediatrics, Wilhelmina Hospital Assen, Europaweg-Zuid 1, 9400 RA Assen, The Netherlands.
A Carin M DasselDepartment of Paediatrics, Deventer Hospital, Nico Bolkesteinlaan 75, 7416 SE Deventer, The Netherlands.
J W F M Corrie JacobsDepartment of Paediatrics, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ Hertogenbosch, The Netherlands.
Paul W T van RijsselDepartment of Paediatrics, Maaziekenhuis Pantein, Dokter Kopstraat 1, 5835 DV Beugen, The Netherlands.
Gerdien A Tramper-StrandersDepartment of Paediatrics, Franciscus Gasthuis en Vlietland, Kleiweg 500, 3045 PM Rotterdam, The Netherlands.ORCID 0000-0002-0228-5375
Annemarie M C van RossumDepartment of Paediatrics, Erasmus MC University Medical Center, Sophia Children's Hospital, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.ORCID 0000-0002-1259-477X
Frans B PlötzDepartment of Paediatrics, Tergooi MC, Laan van Tergooi 2, 1212 VG Hilversum, The Netherlands.ORCID 0000-0003-3212-2048

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of suspected early-onset sepsis (EOS) is undergoing continuous evolution aiming to limit antibiotic overtreatment, yet current data on the level of overtreatment are only available for a select number of countries. This study aimed to determine antibiotic initiation and continuation rates for suspected EOS, along with the incidence of culture-proven EOS in The Netherlands. In this retrospective study from 2019 to 2021, data were collected from 15 Dutch hospitals, comprising 13 regional hospitals equipped with Level I-II facilities and 2 academic hospitals equipped with Level IV facilities. Data included birth rates, number of neonates started on antibiotics for suspected EOS, number of neonates that continued treatment beyond 48 h and number of neonates with culture-proven EOS. Additionally, blood culture results were documented. Data were analysed both collectively and separately for regional and academic hospitals. A total of 103,492 live-born neonates were included. In 4755 neonates (4.6%, 95% CI 4.5-4.7), antibiotic therapy was started for suspected EOS, and in 2399 neonates (2.3%, 95% CI 2.2-2.4), antibiotic treatment was continued beyond 48 h. Incidence of culture-proven EOS was 1.1 cases per 1000 live births (0.11%, 95% CI 0.09-0.14). Overall, for each culture-proven EOS case, 40.6 neonates were started on antibiotics and in 21.7 neonates therapy was continued. Large variations in treatment rates were observed across all hospitals, with the number of neonates initiated and continued on antibiotics per culture-proven EOS case varying from 4 to 90 and from 4 to 56, respectively. The high number of antibiotic prescriptions compared to the EOS incidence and wide variety in clinical practice among hospitals in The Netherlands underscore both the need and potential for a novel approach to the management of neonates with suspected EOS.

Indexed as

anti-bacterial agentantimicrobial stewardshipblood cultureearly-onset sepsisincidenceneonates

Identifiers

PMID38927203
PMCPMC11200437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.